- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04621669
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
November 4, 2020 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Multi-center, Open-lable, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Pgoxin (P-gp Substrates), Rosuvastatin Calcium (BCRP and OATP1B1/1B3 Substrates) and Metformin Hydrochloride (MATE1/2-K Substrates) in Prostate Cancer Patients
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haitao Niu
- Phone Number: 18661803117
- Email: Niuht0532@126.com
Study Contact Backup
- Name: Yu Cao
- Phone Number: 18661809090
- Email: caoyu1767@126.com
Study Locations
-
-
-
Qingdao, China
- Affiliated Hospital of Qingdao University
-
Contact:
- Yu Cao
-
Contact:
- Haitao Niu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to enter the study:
- 18 ≤ age ≤75, male;
- ECOG score of physical condition is 0 ~ 1;
- The expected survival time is at least 3 months;
- Prostate adenocarcinoma confirmed by histological or cytological examination (can be included in mHSPC and mCRPC populations), with no neuroendocrine or small-cell characteristics;CRPC should also meet the following two conditions :(1) serum testosterone level of castration (< 1.7 nmol/L);(2) biochemical progression: prostate-specific antigen (PSA) was increased for 3 consecutive times at an interval of 1 week or more, and increased by more than 50% compared with the lowest value for 2 consecutive times, with PSA > 2 g/L.Or imaging progress: 2 or more new lesions or soft tissue lesions conforming to solid tumor response evaluation criteria were found on bone scan;
The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) :
- the ANC ≧ 1.5 x 109 / L;
- PLT ≧ 80 x 109 / L;
- Hb ≧ 90 g/L; 1.5 x ULN - TBIL ≦;
- ALT and AST≦2.5×ULN;
- 1.5 x ULN Cr ≦;
- GFR ≧ 60 ml/min / 1.73 m2.
- According to the researcher's judgment, it can comply with the experimental scheme;
- In addition, in accordance with the requirements of regulatory authorities, research centers and relevant departments, and based on the judgment of researchers, you shall be tested for COVID-19 screening when necessary;
- Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent.
Exclusion Criteria:
ubjects who meet any of the following criteria will not be admitted to the study:
- Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the washout period of the first drug administration in this study is <4 weeks;
- Plan to receive any other anti-tumor therapy during the study;
- As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study (except for the patients who have participated in ADT treatment before and have been out of the group, and the subjects who are still giving free ADT treatment);
- The presence of intracerebral tumor lesions according to imaging diagnosis;
- Have a history of epilepsy, or have diseases that can induce epileptic seizures within 12 months before the first administration of the drug in this study (including a history of transient ischemic attack, cerebral stroke (except cerebral ischemia lesions found by simple imaging examination), and need to be hospitalized with cerebral trauma and consciousness disorder);
- Active heart disease, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias, within 6 months prior to the first administration of the drug in this study;
- Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery, or other factors affecting drug use and absorption as determined by the investigator;
- Patients with active HBV or HCV infection (HBsAg positive and virus copy number ≥500 IU/mL, HCV antibody positive and HCV RNA higher than the lower limit of analytical method detection) and active syphilis;
- A history of immunodeficiency (including HIV positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation;
- Patients who were unwilling to use effective contraceptive methods during the whole study treatment period and within 3 months after the last administration;
- Allergic constitution, including a history of severe drug allergy or drug allergy;
- Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking within 48 hours before the first dose, or not interrupting smokers during the main study trial, and screening for drug use in the first 3 months with a history of drug abuse or positive drug abuse screening;
- has a history of alcoholism or within 6 months prior to screening often drinkers, namely the essence of drinking more than 14 units of alcohol a week (1 = 285 mL of alcohol content of 5% beer or 25 mL of 40% alcohol liquor or 100 mL wine alcohol content of 12%) or within 48 h before taking the medicine for the first time drinking, or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake during the study period;
- Use of any vitamin product, health product or herb 14 days prior to the first administration;
- Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages containing caffeine, xanthine or alcohol within 48 hours before taking the study drug;Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion;
- Within 2 weeks before the first drug uptake, uptake transporter P-GP, BCRP, OATP1B1/1B3 or MATE1/2-K inhibitors were used, or drugs affecting gastric acid secretion.(Annex I);
- abnormal coagulation function at screening stage (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT> 1.5uln), bleeding tendency or thrombolytic therapy;
- Patients with a history of fainting needle or blood, have difficulty in blood collection or cannot tolerate vein puncture for blood collection;
- Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease, psychosis, etc.) or any other conditions that, in the investigator's judgment, would seriously endanger the patient's safety or affect the patient's completion of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: digoxin, Rosuvastatin calcium,SHR3680
|
240 mg
0.25 mg
10 mg
|
Experimental: metformin hydrochloride ,SHR3680
|
240 mg
500 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to infinite time(AUCinf)for digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax of digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
|
incidence of adverse events/serious adverse event
Time Frame: From ICF signing date to approximate 2 months
|
safety evaluation based on NCI-CTC AE 5.0
|
From ICF signing date to approximate 2 months
|
T1/2 of digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
|
CL/F of digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
|
Vz/F of digoxin, Rosuvastatin calcium, metformin hydrochloride
Time Frame: For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
For digoxin and Rosuvastatin calcium group:Day1 and Day22;For metformin hydrochloride group:Day1 and Day19
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 19, 2020
Primary Completion (Anticipated)
May 12, 2021
Study Completion (Anticipated)
July 5, 2021
Study Registration Dates
First Submitted
November 3, 2020
First Submitted That Met QC Criteria
November 4, 2020
First Posted (Actual)
November 9, 2020
Study Record Updates
Last Update Posted (Actual)
November 9, 2020
Last Update Submitted That Met QC Criteria
November 4, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Enzyme Inhibitors
- Antimetabolites
- Protective Agents
- Cardiotonic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Calcium-Regulating Hormones and Agents
- Digoxin
- Rosuvastatin Calcium
- Calcium
- Metformin
Other Study ID Numbers
- SHR3680-I-DDI-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-drug Interaction,SHR3680
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
University of Southern CaliforniaRecruitingDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingDrug Drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationDrug-drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug Drug InteractionKorea, Republic of
-
ItalfarmacoCompletedDrug-Drug InteractionPortugal
-
Aurinia Pharmaceuticals Inc.CompletedDrug-drug InteractionUnited States
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Nanjing Yoko Biomedical Co., Ltd.CompletedDrug-drug InteractionChina
Clinical Trials on SHR3680
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingCastration-Resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedProstate Cancer | Castration-resistant Prostate CancerChina
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer | Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHepatic Impairment | Healthy ParticipantsChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer MetastaticChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingPatients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Jiangsu HengRui Medicine Co., Ltd.RecruitingProstate Cancer | Biochemical RecurrenceChina